Navigation Links
New medication brings hope of jet lag cure
Date:12/2/2008

A team of researchers from Monash University, The Brigham and Women's Hospital (Boston), Harvard Medical School and Vanda Pharmaceuticals has found a new drug with the potential to alleviate jet lag and sleep disorders caused by shift work.

Dr Shantha Rajaratnam from Monash University's School of Psychology, Psychiatry and Psychological Medicine said tasimelteon, a drug which acts on melatonin receptors in the brain, could be a highly effective treatment for circadian rhythm sleep disorders.

The research was released today in respected publication, The Lancet.

"Our studies show that tasimelteon is able to effectively shift the rhythm of melatonin levels in the body, which are a well-established marker of the human biological clock," Dr Rajaratnam said.

"This drug has the potential to improve the quality and quantity of sleep for patients with transient insomnia caused by jet lag.

"Tasimelteon improved a patient's ability to fall asleep and then stay asleep when bedtime was shifted earlier by five hours.

"This is the equivalent of travelling eastwards and putting your clock back five hours, such as returning from India to Melbourne, or Dubai to Perth.

"About two thirds of all international travellers who cross time zones experience jet lag symptoms, which include disruption of sleep, difficulty getting to and staying asleep, sleepiness during waking hours and gastrointestinal symptoms."

He said the drug could also help those who work at night or early in the morning.

"An estimated one in five work outside the regular nine-to-five pattern. In the United states alone it is estimated 19.7 million people start work between 2.30 and 7 am," Dr Rajaratnam said.

"Our work has shown the drug to be highly potent, having the strongest effect when first taken; a single dose treatment was found to be effective for this type of sleep disturbance."

The drug is in the l
'/>"/>

Contact: Shaunnagh O'Loughlin
shaunnagh.o'loughlin@adm.monash.edu.au
61-448-574-148
Monash University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications
2. Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness
3. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
4. Study: Patient Harm More Common with Patient-Controlled Pain Medication
5. Disclosure of medication can save a patients life
6. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
7. Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions
8. ADHD Medications Dont Pose Cancer Risk
9. New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
10. PharmacyChecker.com Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
11. New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Nov. 28 GAB Robins is pleased to,announce that ... Adjusting,Sales for North American Operations. In this position, Ms. ... and will be responsible for,increasing business development opportunities for ... been with GAB Robins for seven years. Most recently, ...
... Nov. 28 In recognition of,National ... Inc., (http://www.HealthCentral.com ) today has launched ... informs online users about acne,aging skin, ... reliable medical information and a,community forum ...
... N.J., Nov. 28 RadPharm, Inc., a leading,provider ... announced,the completion of a $10 million Series B ... Ampersand Ventures, Adams Street,Partners and Tang Capital Management ... wealth of expertise in medical imaging and clinical,research, ...
... HUBBARD, Ohio, Nov. 28 NanoLogix, Inc. ... that the company has,submitted international patent applications ... China, India, Brazil, and the,EU (European Union). ... anticipated,global roll-out of the company,s BioNanoChannel(TM) rapid,bacteria/microorganism ...
... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin ... industry engaged in the development, manufacture and,distribution ... care products in China, today announced that ... Asia institutional investor conference on,December 5, 2007 ...
... Patient Implanted in San Antonio, TX -, ORANGEBURG, ... began patient enrollment in a national diabetes clinical,trial of ... with type 2 diabetes who are overweight. The study ... United States., The 300-patient trial will evaluate the ...
Cached Medicine News:Health News:The HealthCentral Network Adds Skin Care Site to Its Web Properties 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology 2Health News:China Yingxia to Present at the ICR XChange Asia Institutional Investor Conference 2Health News:MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 2
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... HYDERABAD, India , Aug. 1, 2014 /PRNewswire/ ... manufacturer providing active pharmaceutical ingredients (APIs), ... to customers located in 85 countries, today announced ... year (FY) 2015, ended June 30, 2014. ... affected by work flow re-prioritization to accommodate certain ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... April 29, 2011 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix , today announced ... on Friday, May 6, 2011 before the open of ... a conference call with the investment community at 8:00 ...
... SAN MATEO, Calif., April 29, 2011 ... patch purchased by 321 institutions, up from 239 in Q4 ... Qutenza product revenue Operational focus enables lower planned expense ... Czech Republic by Astellas NGX-1998 Phase 2 clinical trial ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: